The SPIKE Act, proposed by Representatives Horsford and Reed, and the FAIR Drug Pricing Act, proposed by Representatives Jan Schakowsky and Francis Rooney require drug manufacturers to justify large spikes in drug prices.
Anna Eshoo
The Public Record
Anna A. Eshoo is an American politician serving as the U.S. Representative for California's 16th congressional district since 2013. A member of the Democratic Party, she has been an advocate for various issues including healthcare, technology, and environmental protection. Eshoo has played a significant role in shaping policies related to telecommunications and has been involved in efforts to improve access to healthcare for her constituents.
This is why I introduced H.R. 530, the Accelerating Wireless Broadband Development by Empowering Local Communities Act of 2019, overturns FCC regulations limiting the ability of local governments to regulate the deployment of 5G…
This is--it is egregious. Carriers promised to stop the practice but they made the same promises a year ago.
What is lacking at the FCC is strong leadership committed to solve these problems.
You are a great talker. But I am just going to consider that you have said--that you have said no.
Unfortunately, the FCC under the leadership of Chairman Ajit Pai continues to serve the interest of companies at the cost of consumers and local communities, ignore facts and data, limit public transparency, and resist Congressional…
I really think you have to up your game so that next time you come here you have a checklist of what you have accomplished.
There is a nexus between people that are very poor that were it not for the food stamps they get they wouldn't be eating.
I've introduced H.R. 2355, the Regulatory Oversight Barring Obnoxious (ROBO) Calls and Texts Act, which creates a Robocall Division at the FCC to combat the scourge of robocalls.
We're going to follow the money. We're examining the system from beginning to end because in order to fix it, we must understand it, and then, we're going to act.
To the manufacturers, again: Are there any other fees or monies that are associated with manufacturers and PBMs that I have missed?
I especially appreciate Mr. Kennedy's questionings, especially around the biosimilar market.
What gives me--what is a source of inspiration to me here is that there is bipartisan agreement on this.
Medicine is part of public health. We have a responsibility to make sure that medicines reach people.
Our overall goal, as you know, on both sides of the aisle is to see to it that the Congress produces effective legislation that will actually lower the price of prescription drugs for the American people.
I think we are really very happy to have this session here today to try to untangle the drug supply chain.
We've already taken the first step. The House passed two drug bills yesterday, including a bill I sponsored, to increase drug market competition.
I urge all Members of the House to support this bipartisan legislation that is going to move us closer to our overall goal of lowering the cost of prescription drugs for the American people. Mr. Speaker, I yield back the balance of my…





